.2025-04-29-13-18-18.svg)
Time to platelet count ≥150 × 109/L
.2025-04-29-13-19-19.svg)
Time to platelet count ≥150 × 109/L
%20(2).2025-04-29-13-19-36.svg)
*The expression “initial treatment” is used to indicate the intention to use a drug or therapy from the beginning of treatment, although due to the procedures required to obtain the medication it could be delayed for several days.
†All patients received PEX and corticosteroids.
-
Völker LA, Kaufeld J, Balduin G, et al. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2022;21(3):559-572. doi:10.1016/j.jtha.2022.11.010
-
Pascual Izquierdo C, Mingot-Castellano ME, Kerguelen Fuentes AE, et al. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(24):6219-6227. doi:10.1182/bloodadvances.2022008028
-
Scully M, Hunt BJ, Benjamin S, et al; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335. doi:10.1111/j.1365-2141.2012.09167.x
-
Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. doi:10.1182/blood-2016-10-709857
-
Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping “plague.” Annu Rev Med. 2002;53:75-88. doi:10.1146/annurev.med.53.082901.103948
-
Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4):E153-E159. doi:10.1503/ cmaj.160142
-
Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8): 1500-1511. doi:10.1182/blood-2009-09-243790
-
Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860-3867. doi:10.1182/blood-2014-11-551580
-
Goel R, King KE, Takemoto CM, Ness PM, Tobian AAR. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion. 2016;56(6):1451-1458. doi:10.1111/trf.13586
-
Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(7):1448-1452. doi:10.1111/jth.13716
-
Grall M, Azoulay E, Galicier L, et al. Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Am J Hematol. 2017;92(4):381-387. doi:10.1002/ajh.24665
-
Thejeel B, Garg AX, Clark WF, et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: a systematic review. Am J Hematol. 2016;91(6):623-630. doi:10.1002/ajh.24339
-
CABLIVI. Summary of Product Characteristics (SmPC). Sanofi.
-
Scully M, Cataland SR, Peyvandi F, et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi:10.1056/NEJMoa1806311
-
Peyvandi F, Cataland S, Scully M, et al. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021;5(8):2137-2141. doi:10.1182/bloodadvances.2020001834
-
Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733-742 and suppl. doi:10.1182/blood.2020008021
-
Committee for Medicinal Products for Human Use (CHMP). Assessment report: MabThera. European Medicines Agency. 2014.
-
Anti-CD20 monoclonal antibody “Rituxan” [rituximab], approved for additional indication of acquired thrombotic thrombocytopenic purpura. News release. Zenyaku Kogyo Co., Ltd, Chugai Pharmaceutical Co., Ltd. Published February 21, 2020. Accessed March 23, 2024. https://www.chugai-pharm.co.jp/english/news/ detail/20200221160000_705.html
-
Peyvandi F, Scully M, Kremer Hovinga JA, et al; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6): 511-522. doi:10.1056/NEJMoa1505533
-
Dutt T, Shaw RJ, Stubbs M, et al. Real-world experience with caplacizumab in the management of acute TTP. Blood. 2021;137(13):1731-1740. doi:10.1182/ blood.2020007599